GET IN TOUCH
Please lodge your grievances with SEBI at https://scores.gov.in
As per PMLA Amendment, linking of Aadhaar with Demat/Trading account is mandatory. All the existing clients shall link their Aadhaar by 31st March 2018. In case the account is not linked within the aforesaid time limit, it will be blocked till Aadhaar Submission.
As per NSDL Circular No: NSDL/POLICY/2017/0022 dated 17th April 2017, all Individual and entity accounts opened from 1st July 2014 to 31st August 2015 has to submit Foreign Account Tax Compliance Act (FATCA) self-declaration (CLICK HERE TO DOWNLOAD ATTACHED FATCA) till 30th April 2017. All the Account Holders who have opened the Demat Account from the period 1st July 2014 to 31st August 2015 are informed to submit the FATCA self declaration to their nearest DP. In case self certification are not provided till 30th April 2017, the Accounts would be blocked.
As per SEBI Letter on collection of Email Ids and Bank Account Details and with Reference to NSDL Circular No: NSDL/POLICY/2017/0009 dated 28th February 2017, it has been observed that Email Ids, Bank Account Details, Mobile Number, SMS Alert of many existing clients are not linked to their Demat Accounts or updated with their latest Bank Account thereby forcing companies to issue printed cheques/warrants and non-receipt of SMS alerts to the client. It is requested to all existing Account Holders to contact their nearest DP for updation of mentioned details in their Demat Accounts.
All existing Individual Demat Account Holders are advised to submit Aadhaar number along with copy of Aadhaar Card to their nearest FSC's.
Gland Pharma Ltd |
---|
Registered Office: Sy No 143-148 150&151 Nr Gandi, X Roads D P Pally Dundigal, Hyderabad - 500043, Telangana |
Phone: 91-40-30510999 |
Email: investors@glandpharma.com |
Website: www.glandpharma.com |
Initial public offer of 43196968 equity shares of face value of Re. 1 each (equity shares) of Gland Pharma Limited (Company or Issuer) for cash at a price of Rs.1500 Per equity share (including a share premium of Rs.1499 per equity share) aggregating Rs.6479.55 crores (The Offer) comprising a fresh issue of 8,333,333 equity shares aggregating up to Rs. 1250 crores on (The fresh issue) and an offer for sale of 34,863,635 equity shares, including 19,368,686 equity shares by Fosun Pharma Industrial Pte. Ltd (promoter selling shareholder) and 10,047,435 equity shares by Gland Celsus Bio Chemicals Private Limited, 3,573,014 equity shares By Empower Discretionary Trust, and 1,874,500 equity shares by Nilay Discretionary Trust (collectively, the other selling shareholders and collectively With the promoter selling shareholder are referred to as the selling shareholders, and such equity shares, the offered shares) aggregating up to Rs. 5229.55 crores (the offer for sale). The offer shall constitute 26.46% of the post-offer paid-up equity share capital of the company. The face value of Equity shares is Re.1 each. The offer price is Rs.1500 per equity share and is 1500 times the face value of the Equity Shares. The Anchor Investor Offer Price is Rs.1500 per Equity Share. |
Issue | Money Payable On | ||
---|---|---|---|
Opens On | Closes On | Application | Allotment |
09-Nov-2020 | 11-Nov-2020 | ₹ 1,500.00 | ₹ 0.00 |
Minimum Application for shares in Nos : 10 Further Multiples of : 10 | ||
---|---|---|
(₹)Cr. | Lead Managers to the Issue | |
Project Cost | 1,250.00 | Citigroup Global Markets India Pvt Ltd |
Project Financed through Current Offer | 6,479.55 | |
Post Issue Equity Share Capital | 163.28 | |
Issue Price | ₹1,500.00 |
Projects |
---|
Funding incremental working capital requirements of the company |
Funding capital expenditure requirements of the company |
General corporate purposes |
Promoted By |
---|
Fosun Pharma Indust. Pte. Ltd |
Shanghai Fosun Pharma. Group |
Listing At |
---|
BSE |
NSE |
Registrar to the Issue |
---|
Link Intime India Pvt Ltd |
INDIAN INDICES
84,401.59 1,216.79 (1.46%)
25,684.05 268.25 (1.06%)
GLOBAL INDICES
83.95 -0.07 (-0.08%)
18,013.98 440.68 (2.51%)
18258.57 245.41(1.36%)